- Authors' discussion and conclusions contradict the data; original supplemental omitted many neurodevelopmental diagnoses.
- Aluminium adjuvant safety studies are largely underwhelming, irrelevant to injectable aluminium, and not designed to assess neurodevelopmental disorders.
- Updated supplemental shows statistically significant association between higher cumulative vaccine-derived aluminium dose and multiple neurodevelopmental disorders including autism spectrum disorders.
Integr Med (Encinitas). 2026 Aug;25(4):10-14.
ABSTRACT
Andersson et al. published “Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood: A Nationwide Cohort Study” with a discussion and conclusion that contradict the data. Aluminum adjuvant safety studies are largely underwhelming, irrelevant to injectable aluminum, and are not designed to study neurodevelopmental disorders. The manuscript matches the original supplemental, in which many neurodevelopmental diagnoses were deleted, but not the updated supplemental, which shows an association with neurodevelopmental disorder. Neurodevelopmental disorders such as Asperger syndrome (now Level 1 autism spectrum disorder), other pervasive developmental disorders, autistic disorder, and autism spectrum disorder are all found to be statistically significantly associated with a higher cumulative dose of vaccine-derived aluminum.
PMID:42730380 | PMC:PMC13567156
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
